Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04154943

Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma

Cutaneous Squamous Cell Carcinoma Clinical Trial

Official title:
A Phase 2 Study of Neoadjuvant Cemiplimab for Stage II to IV (M0) Cutaneous Squamous Cell Carcinoma (CSCC)

Clinical Trial Summary

The primary objective of the study is to evaluate the efficacy of neoadjuvant cemiplimab as measured by Pathologic complete response (pCR) rate per independent central pathology review. The secondary objectives of the study are: - To evaluate the efficacy of neoadjuvant cemiplimab on measures of disease response, including: - Major pathologic response (mPR) rate per independent central pathology review - pCR rate and mPR rate per local pathology review - ORR prior to surgery, according to local assessment using RECIST 1.1 - To evaluate the efficacy of neoadjuvant cemiplimab on event free survival (EFS), disease free survival (DFS), and overall survival (OS) - To evaluate the safety profile of neoadjuvant cemiplimab - To assess change in surgical plan (ablative and reconstructive procedures) from the screening period to definitive surgery, both according to investigator review and independent surgical expert review - To assess change in post-surgical management plan (radiation, chemoradiation, or observation) from the screening period to post-surgery pathology review, both according to investigator review and independent surgical expert review

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04154943
Study type Interventional
Source Regeneron Pharmaceuticals
Contact
Status Active, not recruiting
Phase Phase 2
Start date March 10, 2020
Completion date September 5, 2025
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Recruiting NCT06036836 - Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) Phase 2
Recruiting NCT03212404 - Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers Phase 1
Terminated NCT04502888 - Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin Phase 1
Recruiting NCT05377905 - Microneedle Array Plus Doxorubicin in Cutaneous Squamous Cell Cancer (cSCC) Phase 1/Phase 2
Recruiting NCT05888844 - A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma Phase 2
Active, not recruiting NCT04050436 - Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer Phase 2
Recruiting NCT05574101 - A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer Phase 2
Completed NCT04616196 - Study of NKTR 255 in Combination With Cetuximab in Solid Tumors Phase 1/Phase 2
Recruiting NCT05108090 - Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck N/A
Recruiting NCT06090266 - A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Recruiting NCT04975152 - Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma Phase 1
Completed NCT01500954 - Microarray Analysis of microRNA Expression Profiles in Cutaneous Squamous Cell Carcinoma N/A
Suspended NCT04916002 - A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer Phase 2
Active, not recruiting NCT04339062 - Cemiplimab in AlloSCT/SOT Recipients With CSCC Phase 1/Phase 2
Recruiting NCT05565417 - Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas Phase 1/Phase 2
Recruiting NCT04664582 - Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck N/A
Not yet recruiting NCT06384820 - Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC) Phase 2
Terminated NCT04596033 - TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy Phase 1
Active, not recruiting NCT06046625 - Needs and Preferences of Patients With Head-neck Cutaneous SCC